Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Rhea-AI Summary

Artivion (NYSE:AORT) will participate virtually in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference with a fireside chat on March 17, 2026 at 9:20 a.m. ET.

According to Artivion, the live webcast will be accessible on the company's Investors page and an archived copy will be available for 90 days.

News Market Reaction – AORT

-0.31%

-0.31% Session close to close

In the Mar 4 session, AORT declined 0.31%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Artivion’s participation in the Oppenheimer healthcare conference, with...

Analysis

This announcement highlights Artivion’s participation in the Oppenheimer healthcare conference, with a virtual fireside chat at 9:20 a.m. ET on March 17, 2026 and a webcast archive available for 90 days. It fits a broader pattern of active investor communication following recent earnings, pivotal trial initiation, and clinical data updates. Investors may focus on strategic messaging around aortic disease solutions, capital allocation, and pipeline milestones discussed during the session.

Key Figures

Conference fireside chat time: 9:20 a.m. ET Webcast archive period: 90 days Current share price: $38.55 +5 more

8 metrics

Conference fireside chat time 9:20 a.m. ET Oppenheimer 36th Annual Healthcare MedTech & Services Conference on Mar 17, 2026

Webcast archive period 90 days Duration webcast replay will be available on Artivion’s website

Current share price $38.55 Price before conference participation announcement

52-week high $48.25 Upper end of 52-week trading range pre-announcement

52-week low $21.97 Lower end of 52-week trading range pre-announcement

Market capitalization $1,841,955,500 Equity value prior to conference news

CEO RSU tax sale 14,911 shares at $38.0249 Form 4 sale to cover tax withholding on vested restricted stock units

Holloway Form 144 proposed sale 2,183 shares Proposed sale tied to restricted stock vesting on 02/27/2026

Historical Context

5 past events · Latest: Feb 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 12	Q4 & FY25 earnings	Positive	-10.0%	Strong Q4 and full-year 2025 results with double-digit revenue growth.
Feb 02	Clinical data update	Positive	+1.1%	Favorable IDE trial outcomes for NEXUS TRIOMPHE and AMDS PERSEVERE.
Jan 29	Earnings call schedule	Neutral	+0.9%	Announcement of Q4 2025 results release and teleconference details.
Nov 06	Q3 2025 earnings	Positive	-5.5%	Strong Q3 revenue, higher adjusted EBITDA, and raised 2025 guidance.
Nov 06	Pivotal trial start	Positive	+2.1%	First patient treated in ARTIZEN pivotal trial for Arcevo LSA stent graft.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows positive fundamental and clinical updates, with shares rising on clinical/pipeline milestones but selling off after strong earnings reports, indicating occasional divergence between fundamentals and immediate price reaction.

Recent Company History

Over the past several months, Artivion reported strong financial performance and steady clinical progress. Q3 and Q4 2025 earnings highlighted double-digit revenue growth, rising adjusted EBITDA, and raised full-year guidance, yet shares fell 5.54% and 9.96% after those reports. In contrast, positive trial data for NEXUS TRIOMPHE and AMDS PERSEVERE, and the first patient in the ARTIZEN pivotal trial, saw modest gains of 1.13% and 2.13%. This conference participation fits into an ongoing pattern of active investor communication around its aortic disease portfolio.

Key Terms

form 4, form 144, restricted stock units, sell to cover, +4 more

8 terms

form 4 regulatory

"title": "[Form 4] ARTIVION, INC. Insider Trading Activity""

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

View in glossary

form 144 regulatory

"The issuer filed a <b>Form 144</b> related to the proposed sale"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

View in glossary

restricted stock units financial

"shares were sold automatically to cover tax withholding upon restricted stock unit vesting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"through a “sell to cover” arrangement and did not represent a discretionary trade"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

pma regulatory

"trial is intended to support a U.S. <b>PMA</b> submission and estimates an incremental"

PMA stands for Premarket Approval, the U.S. Food and Drug Administration’s highest-level review for high-risk medical devices. It’s a thorough evaluation to confirm a device is safe and effective before it can be sold, like a final safety inspection and license to operate. Investors care because receiving PMA can open a significant revenue stream, while delays or rejection can postpone sales and reduce a company’s value.

ide trial medical

"two IDE trials. <b>NEXUS TRIOMPHE</b> (n=94) reported 94% survival"

An IDE trial is a regulated clinical study that lets a company test a medical device in patients under an Investigational Device Exemption from the U.S. regulator; it’s essentially a formal permit to gather safety and effectiveness data before broad commercial approval. For investors, an IDE trial is a major de-risking step and milestone—successful results move a device closer to market approval and revenue, while delays or negative outcomes can materially affect a company’s value, similar to how a road-test permit lets a car maker prove a new model is safe before mass production.

aortic arch medical

"Hybrid Stent Graft System</b> for acute and chronic aortic arch pathologies"

The aortic arch is the curved top portion of the body's main artery that carries blood from the heart and branches off to supply the brain, arms and upper body — think of it as a highway interchange where major roads split from the main route. It matters to investors because diseases, injuries or surgeries involving the aortic arch often require specialized drugs, devices or procedures that drive clinical trials, regulatory reviews, revenue opportunities and potential liability for companies in healthcare and medical technology.

webcast technical

"A live webcast can be accessed through Artivion's website"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ATLANTA, March 3, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate virtually at the upcoming Oppenheimer 36^th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 9:20 a.m. ET on Tuesday, March 17, 2026.

A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.

About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Contacts:

Artivion	Gilmartin Group LLC
Lance A. Berry	Brian Johnston
Executive Vice President,	Laine Morgan
Chief Operating Officer &	Phone: 332-895-3222
Chief Financial Officer	investors@artivion.com
Phone: 770-419-3355

View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-to-participate-in-the-oppenheimer-36th-annual-healthcare-medtech--services-conference-302703016.html

SOURCE Artivion, Inc.

FAQ

When will Artivion (AORT) present at the Oppenheimer Healthcare MedTech conference in 2026?

Artivion's virtual fireside chat is scheduled for March 17, 2026 at 9:20 a.m. ET. According to Artivion, the session is part of the Oppenheimer 36th Annual Healthcare MedTech & Services Conference and will be presented virtually.

How can investors watch the Artivion (AORT) webcast for the March 17, 2026 presentation?

Investors can watch the live webcast via Artivion's Investors page on the company website. According to Artivion, the live stream will be available at the scheduled time and archived for 90 days after the event.

Will the Artivion (AORT) webcast from the Oppenheimer conference be available after March 17, 2026?

Yes, an archived copy will be available for 90 days following the live event. According to Artivion, the recording will be posted on the company's Investors page for on-demand access during that period.

What topics will Artivion (AORT) cover during the March 17, 2026 fireside chat at Oppenheimer?

The announcement states Artivion will participate in a virtual fireside chat at the conference but does not list topics. According to Artivion, investors should view the webcast for the company's presentation and any topic details discussed during the session.

Where is the Artivion (AORT) webcast hosted for the Oppenheimer 36th Annual Healthcare MedTech & Services Conference?

The webcast is hosted on Artivion's official website, on the Investors page. According to Artivion, the live stream and the subsequent 90-day archived recording will both be available through that investor-facing webpage.